Immunocore Holdings plc American Depositary Shares (IMCR) — Analysis Summary
Immunocore Holdings plc American Depositary Shares (IMCR) has a market cap of $1.65B with year-over-year revenue growth of +29.0%. Net margin stands at -8.9%. The stock trades at a P/E ratio of -60.0.
Key Takeaways
- Revenue changed +29.0% year-over-year
- Net margin of -8.9%
- P/E ratio of -60.0
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, IMCR posted revenue growth of +29.0% and trades at a P/E of -60.0.
Immunocore Holdings plc American Depositary Shares (IMCR)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -2.8x — earnings do not cover interest payments
The latest filing shows negative free cash flow.
Gross margin at 98.9% — verify: very few businesses sustain >90% gross margin outside pure software/IP
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
524
Headquarters
OXFORDSHIRE, X0
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.